Company highlights
- Mature pipeline with two phase III drugs and one in registration
- Seven products in clinical development
- Potential for earlier approval of first product, in 2009
- ASA404: partnered with Novartis
– with blockbuster potential in lung cancer
– US co-marketing option with Novartis
– target 2011 filing - Xanafide: potential first product registration for secondary AML
- Oral fludarabine: attractive low-risk niche oncology opportunity
- AS1411: first aptamer in oncology, with broad potential
- Flt3 program: attractive divestible asset in auto-immune diseases
- Strong cash position to support all priority programs
Back to top